ADAR1 Capital Management LLC Trims Position in Royalty Pharma plc (NASDAQ:RPRX)

ADAR1 Capital Management LLC lowered its position in Royalty Pharma plc (NASDAQ:RPRX) by 95.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 49,963 shares of the biopharmaceutical company’s stock after selling 1,046,703 shares during the quarter. ADAR1 Capital Management LLC’s holdings in Royalty Pharma were worth $1,275,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Aster Capital Management DIFC Ltd increased its holdings in Royalty Pharma by 36.7% in the 4th quarter. Aster Capital Management DIFC Ltd now owns 4,890 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 1,312 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Royalty Pharma by 32.0% in the fourth quarter. Russell Investments Group Ltd. now owns 1,855,791 shares of the biopharmaceutical company’s stock valued at $47,319,000 after acquiring an additional 449,551 shares in the last quarter. Aviva PLC lifted its stake in Royalty Pharma by 1,522.0% in the fourth quarter. Aviva PLC now owns 229,069 shares of the biopharmaceutical company’s stock worth $5,844,000 after acquiring an additional 214,946 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Royalty Pharma by 29.1% in the 4th quarter. Wells Fargo & Company MN now owns 70,120 shares of the biopharmaceutical company’s stock valued at $1,789,000 after purchasing an additional 15,790 shares during the last quarter. Finally, Integrated Quantitative Investments LLC purchased a new stake in shares of Royalty Pharma during the 4th quarter worth $390,000. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on RPRX. Citigroup reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $41.60.

Royalty Pharma Stock Down 2.1 %

Shares of NASDAQ RPRX opened at $31.11 on Monday. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The firm’s 50-day moving average is $32.52 and its two-hundred day moving average is $28.97. The company has a market capitalization of $17.93 billion, a PE ratio of 21.46, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Equities analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.83%. The ex-dividend date was Friday, February 21st. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is 60.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.